On July 13, the US Food and Drug Administration (FDA) approved Tremfya (guselkumab) to treat moderate to severe plaque psoriasis. Tremfya, developed by Johnson & Johnson’s subsidiary Janssen, of Beers, Belgium, is the first and only human monoclonal antibody (mAb) that selectively blocks…
Fonte: VOLUME 35 NUMBER 9 SEPTEMBER 2017 NATURE BIOTECHNOLOGY
Para acessar a publicação na íntegra clique aqui